Still reeling from rejection, BioMarin reports a glimpse of those 2-year valrox data FDA was looking for — but is it enough to change regulators' minds?
BioMarin now has the Phase III data it needs to refile valrox, its gene therapy for hemophilia A, at the EMA — and possibly convince the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
